Implementation of De-Escalation Algorithm in patients with ventilator-associated pneumonia at two anaesthesiological intensive care units (ICUs) of Charité - University Medicine Berlin

Implementation of De-Escalation Algorithm in patients with ventilator-associated pneumonia at two anaesthesiological intensive care units (ICUs) of Charité - University Medicine Berlin: a prospective observational single centre trial

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN80881420

Enrollment

200

Registered

2009-06-29

Start date

2009-03-03

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ventilator-associated pneumonia Respiratory Pneumonia, organism unspecified

Interventions

After distribution of the de-escalation algorithm, clinician teams will be asked to treat the patients with suspicion of VAP according to algorithm. It will be left to their discretion, whether to adh

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Intensive care unit (ICU) patients aged greater than 18 years, either sex 2. On mechanical ventilation for greater than or equal to 48 hours 3. Presenting with systemic inflammatory response syndrome (SIRS) and radiologically suggested new infiltrate

Exclusion criteria

Exclusion criteria: 1. Aged less than 18 years 2. Other unknown infectious focus 3. Severe immune suppression (defined as corticosteroid doses of more than 7.5 mg of prednisolone equivalent for longer than 30 days, or other immuno-suppressive drugs) 4. Acquired immune deficiency syndrome (AIDS)/human immunodeficiency virus (HIV) 5. Moribund patients

Design outcomes

Secondary

Measure	Time frame
1. Number of antibiotic-free days 2. Number of ventilator-free days 3. Number of organ dysfunctions 4. Length of ICU stay 5. Length of hospital stay 6. Rate of super-infections with multidrug resistant (MDR) species (P. aeruginosa, methicillin-resistant S. aureus etc.) 7. Therapy costs All assessed at the end of data collection.	—

Primary

Measure	Time frame
Number of patients with appropriate de-escalation according to VAP algorithm, assessed at the end of data collection.	—

Countries

Germany

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026